mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer

 mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer

mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer

Shots:

  • The EC has approved MB02 biosimilar to Avastin (Bevacizumab) in the EU for the treatment of carcinoma of the colon or rectum, BC, NSCLC, RCC, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix
  • Mabxience’s MB02 to be marketed as Alymsys and Oyavas both show comparable quality, safety & efficacy to Avastin (bevacizumab)
  • The launch of Bevacizumab has provided high quality, affordable medicine and opportunity to the healthcare system and improve patient access to biological treatments throughout the EU

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Adobe Stock

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post